Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AcuMedic To Promote TCM In EU Market

This article was originally published in PharmAsia News

Executive Summary

At a recent Sino-UK TCM modernization and industrialization seminar in Chongqing, UK-based Mei Group PLC disclosed that its subsidiary AcuMedic will promote the entry of TCM into the EU mainstream market by various means. With more western consumers accepting TCM, UK experts at the meeting said they will apply modern biotechnology to Chinese herbal research. At the same time, they will step up efforts to push for TCM standardization to meet EU requirements. The UK side hopes to leverage on Chongqing, the most important TCM base in South west China. By collaborating with the local TCM industry as well as R&D institutions in production and test technology, raw material purchase and talent training, the partners aim to jointly boost TCM internationalization. (Click here for more - Chinese Language)

You may also be interested in...

Spring Shopping: Ping An Bets On Shionogi, TCMs In Coronavirus Aftermath

China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.

EU Scientific Committee Affirms Safety Of Anti-Dandruff Zinc Pyrithione Under Threat Of Cosmetic Ban

The Scientific Committee for Consumer Safety upholds that zinc pyrithione is safe for use in rinse-off anti-dandruff hair products at levels up to 1%. In recent years, the cosmetics industry has pushed for a 2% ceiling on ZPT content in that capacity – with considerable inroads made. Where that proposal now stands vis-à-vis the ingredient’s pending CMR 1B classification and shifting political sands is uncertain.

Otsuka Dermatitis Candidate Looks Good At Phase III

New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts